Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%Salomon M. Stemmer, Nicky Liebermann, Noa Ben-Baruch et al.|Cancer Research|2016Cited by 23
First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) resultSalomon M. Stemmer, Noa Ben-Baruch, M. Steiner et al.|Annals of Oncology|2016Cited by 3
Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 yearsSalomon M. Stemmer, N Ben Baruch, Shulamith Rizel et al.|Cancer Research|2018Cited by 0